TGFB1 and osteogenesis imperfecta: A phase 1 dose-escalating clinical trial (NCT03064074) included eight adults with OI for 6 months and evaluated the safety of an anti-TGF-β monoclonal human antibody (Fresolimumab), an antibody that neutralizes all three TGF-β homodimers.